Track record · closed signal

Stoke Therapeutics, Inc. (STOK) — closed signal from February 6, 2026

Partial Published before the outcome was known, scored automatically when the window closed on May 7, 2026.

Predicted vs. what happened

STOK price · publication thesis → realized outcomesplit-adjusted

$32.60 – $34.10Entry zone — fair-value band

$33.47Published — price the day we called it

$42.84Target — the price the thesis aimed for

$40.22Peak — highest point inside the window, not a realized return

$32.79Window close — end-of-window price, context only

What happened

Partial

Reached 72% of the predicted growth at its peak, without hitting the target.

Peak price

$40.22

peak on March 10, 2026 — not a realized return

Peak gain

+20.2%

peak, from the publication price

Window close

$32.79

end-of-window price, context only

Days to target

—

Window

February 6, 2026 – May 7, 2026

The thesis — published February 6, 2026

Predicted growth

+28%

over the measurement window

Target price

$42.84

the price the thesis aimed for

Entry zone

$32.60 – $34.10

the fair-value band we waited for

Price at publication

$33.47

published February 6, 2026

Confidence

89%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Stoke's recent news makes its stock more likely to keep moving upward for the next few months. Updates in January made the timing for the big Phase III trial clearer, and signing a new headquarters lease shows the company is preparing to sell treatments. If investors stay willing to buy biotech stocks, momentum can continue, but shares swing sharply, so buy only on calm pullbacks.

Primary drivers

Clearer Phase III timing makes the program easier to track and trust
New HQ and planning signal the company is preparing to sell treatments
Price is improving compared with many other biotech stocks
When investors favor biotech, gains can accelerate quickly

How it played out

STOK: thesis rose partway but missed the target

Lyra published STOK at $33.47 on February 6, 2026. The thesis expected 28% growth over a short-term window, with a target of $42.84. It pointed to clearer Phase III timing, a new headquarters lease, planning for treatment sales, stronger price action versus many biotech stocks, and possible support if investors favored biotech.

Inside the window, STOK rose to $40.22 on March 10, 2026. That was a 20.2% peak gain, but it stayed below the target. By May 7, 2026, it ended at $32.79. The thesis partially played out on momentum, then missed on the full target and the final price.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All STOK signals